Gleason Score News and Research

RSS

New genetic test may give men better view on how to deal with prostate cancer risk

Scientists are reporting a test which can predict which patients are most at risk from aggressive prostate cancer, and whether they suffer an increased chance of treatment failure.

27 Mar 2017

Research finds disparity in rates of prostate cancer treatment among African-American, Hispanic men

African-American and Hispanic men in the United States are less likely to receive therapy for prostate cancer compared to Caucasian men — even when they have more aggressive disease, according to new research from Roswell Park Cancer Institute and Vanderbilt University Medical Center.

7 Oct 2016

Intermediate risk prostate cancer patients can achieve survival benefit with brachytherapy alone

For men with intermediate risk prostate cancer, radiation treatment with brachytherapy alone can result in similar cancer control with fewer long-term side effects, when compared to more aggressive treatment that combines brachytherapy with external beam therapy (EBT), according to research presented today at the 58th Annual Meeting the American Society for Radiation Oncology.

27 Sep 2016

Management of prostate cancer varies by race

A study published in The Journal of Urology® indicates that treatment for low-risk prostate cancer, rather than watchful waiting, is most likely to be sought by black men.

29 Jul 2016

Active surveillance improves health related quality of life in low risk prostate cancer patients

Active surveillance (AS) has become an increasingly important alternative to surgery, chemotherapy, or radiation treatment for men diagnosed with low risk prostate cancer.

25 Jul 2016

Changes in benign tissue adjacent to prostate tumors could better predict recurrence

Changes in benign tissues next to prostate tumors may provide an early warning for patients at higher risk for biochemical recurrence after a radical prostatectomy, a study by researchers at Case Western Reserve University and Johns Hopkins Medical Institutions shows.

6 Jul 2016

Study assesses risk factors for metastases in prostate cancer patients on active surveillance

Radical treatment such as surgery and radiation for localized prostate cancer may cause significant side effects. Active surveillance is increasingly accepted as an option for treating patients with clinically insignificant disease to maintain their quality of life.

12 Apr 2016

Experimental urine test identifies 92% of men with elevated PSA levels

An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA (prostate-specific antigen) levels who had high-grade cancers, according to a study published today in JAMA Oncology online.

1 Apr 2016

ANGLE’s Parsortix system may be used for detection of prostate cancer, Barts patient data suggests

ANGLE plc, the specialist medtech company, is delighted to announce that the results of Barts Cancer Institute’s ongoing work with ANGLE’s Parsortix system have provided evidence in support of the use of Parsortix in the detection and assessment of prostate cancer.

22 Mar 2016

ZYTIGA plus prednisone provides overall survival benefit in men with early and less aggressive mCRPC

Janssen-Cilag International NV today announced that data from a post-hoc analysis of the Phase 3 COU-AA-302 trial showed that ZYTIGA (abiraterone acetate) plus prednisone provided an 11.8 months overall survival (OS) benefit (53.6 months vs 41.8 months; HR = 0.61 [95% CI, 0.43-0.87]; p = 0.0055), compared to an active control of placebo plus prednisone, in men with early and less aggressive chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

15 Mar 2016

New study finds link between vitamin D deficiency and aggressive prostate cancer

A new study provides a major link between low levels of vitamin D and aggressive prostate cancer. Northwestern Medicine research showed deficient vitamin D blood levels in men can predict aggressive prostate cancer identified at the time of surgery.

2 Mar 2016

African American men with prostate cancer have significantly lower PSA density than Caucasian men

A new study published in The Journal of Urology revealed that African American men with Gleason score 3+3=6 prostate cancer (PCa) produce less prostate specific antigen (PSA) and have significantly lower PSA density (PSAD) than Caucasian men. These findings could have important implications when selecting patients for inclusion in active PCa surveillance programs.

5 Jan 2016

New research finds five different types of prostate cancer

New research has revealed that five different types of prostate cancer exist. How will this discovery change the outlook of prostate cancer screening? World renowned robotic prostate cancer surgeon, Dr. David Samadi, evaluates.

25 Aug 2015

PSMA PET imaging more precise than MR imaging for detection of high-grade prostate cancer lesions

A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in the July 2015 issue of The Journal of Nuclear Medicine, is significant for patients with suspected prostate cancer that has not been confirmed by standard biopsy.

21 Aug 2015

Genomic Health announces Medicare coverage for Oncotype DX prostate cancer test

Genomic Health, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued its final local coverage determination (LCD) approving coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States.

17 Aug 2015

Prostate cancer discovery may improve treatment strategies

Scientists from Cancer Research UK have discovered that there are five different types of prostate cancer and have found a way of distinguishing between them. These findings could change how the condition is treated, providing more effective therapies where they are needed the most.

30 Jul 2015

Cancer Research UK scientists identify five distinct types of prostate cancer

Cancer Research UK scientists have for the first time identified that there are five distinct types of prostate cancer and found a way to distinguish between them, according to a landmark study published today in EBioMedicine.

30 Jul 2015

Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer, according to a new study from Penn Medicine published this week in JAMA Oncology. Already-high survival rates for men with low-risk prostate cancer were unaffected by higher radiation dosages compared to lower radiation dosages.

17 Jul 2015

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).

2 Jun 2015

Decipher Prostate Cancer Classifier predicts metastasis in patients treated with salvage radiation therapy

GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant predictor of metastasis in patients treated with postoperative salvage radiation therapy.

30 May 2015